Thank you Mozzarc for this most excellent post.
Fantastic work.
I have a small group of elite investor friends who when we discuss PAR and it's prospects we always come back to Humira.... Biggest selling drug in the world, US $20 Billion last year with a raft of negative side effects and we always postulate that if Humira can do it, well, then Paradigm (with a market 10x the size of RA) can do it too.
We're all of the mind that Zilosul will one day become the biggest selling drug in the world.
Whilst Humira comes with many and major ill side effects, Zilosul often comes with many and major positive side effects (how many stories have we now heard of Zilosul treating and curing other pain experienced by the patient aside from the knee or hip osteoarthritis for which they were primarily taking the drug.....many) so that's a major difference in our favor.
Never heard of any negative side effects from anyone taking Zilosul.
PAR and Zilosul are on the way, patience is a virtue...... and will be rewarded.
- Forums
- ASX - By Stock
- PAR
- The Humira comparative, and how about a bonus?
The Humira comparative, and how about a bonus?, page-8
-
-
- There are more pages in this discussion • 16 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add PAR (ASX) to my watchlist
(20min delay)
|
|||||
Last
20.5¢ |
Change
-0.005(2.38%) |
Mkt cap ! $71.73M |
Open | High | Low | Value | Volume |
21.0¢ | 21.0¢ | 19.5¢ | $323.1K | 1.612M |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
1 | 324 | 20.5¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
21.0¢ | 52928 | 5 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
1 | 324 | 0.205 |
4 | 51564 | 0.200 |
6 | 188903 | 0.195 |
19 | 418023 | 0.190 |
7 | 134000 | 0.185 |
Price($) | Vol. | No. |
---|---|---|
0.210 | 52928 | 5 |
0.215 | 16833 | 2 |
0.220 | 23800 | 4 |
0.225 | 42062 | 1 |
0.230 | 78202 | 7 |
Last trade - 16.10pm 28/10/2024 (20 minute delay) ? |
Featured News
PAR (ASX) Chart |